Compare CBC & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBC | KYMR |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | 3036 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.4B |
| IPO Year | N/A | 2020 |
| Metric | CBC | KYMR |
|---|---|---|
| Price | $29.48 | $107.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 26 |
| Target Price | $28.67 | ★ $107.72 |
| AVG Volume (30 Days) | 792.5K | ★ 970.4K |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $12.15 | $10.61 |
| Revenue Next Year | $6.34 | $8.17 |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.50 | $36.88 |
| 52 Week High | $29.92 | $130.05 |
| Indicator | CBC | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 62.68 | 69.41 |
| Support Level | $26.86 | $68.35 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.85 | 6.85 |
| MACD | 0.06 | 3.23 |
| Stochastic Oscillator | 85.11 | 60.04 |
Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses. Its operating segments include Consumer, Commercial, and Wealth Management. The company generates the majority of its revenue from the Commercial segment, which provides full-service relationship banking solutions to businesses, agencies, and community organizations, including commercial, small business, and government clients. The segment also offers business payment solutions such as treasury management services, merchant services, and commercial bank card products.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.